Momenta Phamaceuticals, Inc. (MNTA) Tops Q1 EPS by 2c; Updates FY14 Outlook

Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q1 EPS of ($0.53), $0.02 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $10.79 million versus the consensus estimate of $8.41 million.

Today, Momenta updated its 2014 financial guidance: total operating expenses, excluding stock-based compensation and net of collaborative revenues, are expected to average $28 to $30 million per quarter. For 2014, Momenta is projecting that its net cash usage, excluding revenue from the potential launch of M356, will average approximately $28 million per quarter, with quarterly cash burn in the second half of 2014 partially offset by an expected $19 million from milestone payments earned under the Baxter collaboration.

For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral